注册 | 登录
点击这里给我发消息
所有产品
  • 所有产品
  • 一抗
  • 裂解液
>   首页   >   产品   >   一抗   >   免疫学   >   TRIM22 antibody - N-terminal region   

TRIM22 antibody - N-terminal region

Rabbit Polyclonal Antibody

     
  • 1 - TRIM22 antibody - N-terminal region AI16256

    WB Suggested Anti-TRIM22 Antibody Titration: 0.2-1 μg/ml
    Positive Control: Human brain
  • 产品详情
  • 实验流程
  • 背景知识
Product Information
Application
  • Applications Legend:
  • E=ELISA
  • WB=Western Blotting
  • IHC=Immunohistochemistry
  • IHC-P=Immunohistochemistry (Paraffin)
  • IP=Immunoprecipitation
  • IF=Immunofluorescence
  • IC=Immunochemistry
  • ICC=Immunocytochemistry
  • FC=Flow Cytometry
  • DB=Dot Blot
WB
Primary Accession Q8IYM9
Other Accession NM_006074, NP_006065
Reactivity Human
Predicted Human
Host Rabbit
Clonality Polyclonal
Calculated MW 56947 Da
Additional Information
Gene ID 10346
Alias Symbol GPSTAF50, RNF94, STAF50
Other Names E3 ubiquitin-protein ligase TRIM22, 6.3.2.-, 50 kDa-stimulated trans-acting factor, RING finger protein 94, Staf-50, Tripartite motif-containing protein 22, TRIM22, RNF94, STAF50
Format Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose.
Reconstitution & Storage Add 50 ul of distilled water. Final anti-TRIM22 antibody concentration is 1 mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at 20°C. Avoid repeat freeze-thaw cycles.
PrecautionsTRIM22 antibody - N-terminal region is for research use only and not for use in diagnostic or therapeutic procedures.
Protein Information
Name TRIM22
Synonyms RNF94, STAF50
Function Interferon-induced E3 ubiquitin ligase that plays important roles in innate and adaptive immunity (PubMed:25683609, PubMed:35777501). Restricts the replication of many viruses including HIV-1, encephalomyocarditis virus (EMCV), hepatitis B virus (HBV), hepatitis C virus (HCV) or Zika virus (ZIKV) (PubMed:25683609, PubMed:35777501, PubMed:36042495). Mechanistically, negatively regulates HCV replication by promoting ubiquitination and subsequent degradation of viral NS5A (PubMed:25683609). Also acts by promoting the degradation of Zika virus NS1 and NS3 proteins through proteasomal degradation (PubMed:36042495). Acts as a suppressor of basal HIV-1 LTR- driven transcription by preventing Sp1 binding to the HIV-1 promoter (PubMed:26683615). Also plays a role in antiviral immunity by co- regulating together with NT5C2 the RIGI/NF-kappa-B pathway by promoting 'Lys-63'-linked ubiquitination of RIGI, while NT5C2 is responsible for 'Lys-48'-linked ubiquitination of RIGI (PubMed:36159777). Participates in adaptive immunity by suppressing the amount of MHC class II protein in a negative feedback manner in order to limit the extent of MHC class II induction (PubMed:35777501).
Cellular Location Cytoplasm. Nucleus Nucleus speckle. Nucleus, Cajal body. Note=Localizes predominantly to the nucleus, found in cytoplasm to some extent. Forms distinct nuclear bodies that undergo dynamic changes during cell cycle progression Nuclear bodies start to form in the early G0/G1 phase but become speckle-like in the S-phase and completely dispersed in mitosis. 35% of TRIM22 nuclear bodies overlap or are found adjacent to Cajal bodies
Tissue Location Strongly expressed in peripheral blood leukocytes, spleen, thymus, and ovary. Expressed at basal levels in other tissues
Research Areas

For Research Use Only. Not For Use In Diagnostic Procedures.

BACKGROUND

Interferon-induced antiviral protein involved in cell innate immunity. The antiviral activity could in part be mediated by TRIM22-dependent ubiquitination of viral proteins. Plays a role in restricting the replication of HIV-1, encephalomyocarditis virus (EMCV) and hepatitis B virus (HBV). Acts as a transcriptional repressor of HBV core promoter. May have E3 ubiquitin-protein ligase activity.

REFERENCES

Tissot C.,et al.J. Biol. Chem. 270:14891-14898(1995).
Reymond A.,et al.EMBO J. 20:2140-2151(2001).
Obad S.,et al.Oncogene 23:4050-4059(2004).
Duan Z.,et al.Biochem. Biophys. Res. Commun. 374:502-506(2008).
Barr S.D.,et al.PLoS Pathog. 4:E1000007-E1000007(2008).

FeedBack

终于等到您。ABCEPTA(百远生物)抗体产品。
点击下方“我要评价 ”按钮提交您的反馈信息,您的反馈和评价是我们最宝贵的财富之一,
我们将在1-3个工作日内处理您的反馈信息。

如有疑问,联系:0512-88856768 tech-china@abcepta.com.


我要评价